Podcast by Future Science Group
Tech Digest: bioanalysis of nitrosamine impurities
Tech Digest: bioanalysis of nitrosamine impurities by Future Science Group
The evolution of PCR: From q to dd and beyond
PCR has evolved rapidly over the last few years, an evolution that has been dramatically accelerated by the COVID-19 pandemic. New technologies and approaches have been brought to the fore and the full range of applications for which this technique can be applied have been highlighted, from diagnostics to basic disease research and immunology.
This episode explores this evolution, looking at how challenges presented by the pandemic forced the hand of researchers to think outside the box and build on lesser-known PCR technologies. Here, Eddy van Collenburg, Market Development Specialist at Bio-Rad, provides his insight into how ddPCR rose to prevalence during this time and explains how the technology is being used to enable trade, detect new variants and is being used outside of the pandemic.
Discover the key role that ddPCR can play in gene therapy research, liquid biopsies, cancer research, single-cell studies and more, in this fascinating overview of the development of PCR and where the technique can go in the future.
Introduction: 00:00-01:30Why was qPCR established as the gold standard for detection? 01:30-03:40Limitations of qPCR during the pandemic 03:40-05:05New varieties of PCR for faster results: 05:05-05:40New varieties for more accurate results: 05:40-06:45ddPCR working principle and advantages: 06:45-09:00Nonclinical ddPCR applications for COVID-19: 09:00-10:45ddPCR in variant detection: 10:45-12:05ddPCR in gene therapy research: 11:05-12:30Liquid biopsy and cancer research: 12:30-15:20Combining ddPCR with NGS in research: 15:20-16:15What are some of the applications of ddPCR that you find most exciting? 16:15-17:10 Applications of ddPCR in single-cell studies 17:10-21:00Improvements in ddPCR: 21:00-21:45 Tips for best practice when using ddPCR: 21:45-22:50What would you ask for to improve ddPCR? 21:50-24:20
Revitalising the western blot
Love it or hate it, western blotting forms the bedrock of countless studies across numerous disciplines. Explore its history, development and applications in this episode all about the marmite of life science techniques.
Guiding me through the hand wringing, hair follicle destroying history and process of western blotting, and hopefully explaining the beauty and potential of the technique - is Kenneth Oh, Senior Project Manager at Bio-Rad Laboratories.
Kenneth reveals some of the latest developments in western blotting. Revealing how researchers are now able to validate the success of each stage of a western blot and work with smaller samples, Kenneth provides key tips for ensuring each of your western blots is a triumph.
History of western blotting: 01:15-3:50
What makes western blotting so tricky? 03:50-05:30
Stepwise optimization: 05:30-06:50
Stain-free western blotting: 06:50-08:50
The different variants of western blotting: 08:50-10:20
The right blot for the right application: 10:20-11:30
The most exciting developments in western bloting:11:30-13:35
New horizons for western blotting: 13:35-15:25
The impact of multiplex-western blotting: 15:25-16:30
Tips for best practice: 16:30-18:10
The future of western blotting: 18:10-20:30
Yearning for automation: 20:30-21:30
Immunoassay applications: a podcast with John Chappell
Immunoassay applications: a podcast with John Chappell by Future Science Group
Molecular therapeutics: how far have we come and what is on the horizon?
Uncover the history of molecular therapeutics, the staggering current applications and developments of these therapeutics and what their future could hold, in this episode of Talking Techniques.
To explore the field of molecular therapeutics and provide an insight into their production, is Aaron Clauson, Product Manager at Zymo research. First, we cover the ins and outs of targeting the therapies and how to select the correct type of molecular therapeutic to begin developing a drug for a specific disease, before looking at some of the setbacks and safety errors that have occurred during the development of molecular therapeutics and how researchers have learned from these tragic events.
Aaron also highlights the vital role of plasmids in almost all molecular therapeutic development, detailing the importance of keeping plasmid solutions and transfections free of endotoxins, revealing key solutions for avoiding these contaminants.
Listen today to get all you need to know about molecular therapeutics, from their inception to their most exciting examples and how we can better communicate their benefits to the public in order to avoid mistrust and confusion - as has occurred during the COVID-19 pandemic.
Contents:What counts as a molecular therapeutic? 01:45-02:40Well known molecular therapeutics 02:40-05:00What can molecular therapeutics achieve that synthetic chemicals can’t? 05:00-05:55Targeting molecular therapeutics and picking the right type of therapeutic 05:55-08:25Selecting the appropriate molecular therapeutic 08:35-11:00Setbacks and safety concerns in gene therapies 11:00-15:45Preventing off-target effects in gene therapies 15:45-17:35Challenges in the development of molecular therapeutics 17:35-19:05 Plasmids in molecular therapeutic development 19:05-23:55 Avoiding endotoxins: 23:55-27:45What fields do you find most exciting? 27:45-28:50Better communication of gene therapies to the public 28:50-32:00 “security agencies detecting molecular therapeutics” 29:10Improving molecular therapeutic development: 32:00-37:10
Adeno-associated viral therapies: harnessing the power of HPLC
This episode centers on the critical role that high-performance liquid chromatography (HPLC) plays in the production of adeno-associated viral (AAV) therapies, the latest advances in AAV design and the next steps in their development.
Filling me in on all things HPLC and AAVs is Bella Neufeld, Director of R&D at Teknova. Bella reveals the essential validation and quality control steps required for the production of successful and safe AAV therapies and the role that both HPLC and liquid chromatography–mass spectrometry (LCMS) play in these steps. We also explore the latest development targets for these therapies, looking at how AAVs can be targeted to specific sites and tissues before descending into the treacherous topic of reproducibility in the field.
Listen today to find out the latest tips for best practice when working with HPLC, LCMS the advantages of LCMS over other analytical techniques to assess empty and full capsids and the key principles of AAV production!
ContentsIntro: 00:00-01:25Explaining HPLC and its benefits: 01:25-03:30Developing adeno-associated viruses: 03:30-05:25 Chromatography in validation vs production of AAVs: 05:25-06:15Quality control vs hands on time: 06:15-07:35 Challenges in AAV production: 07:35-08:55Examining the level of empty and full capsids: 08:55-10:00The role of LCMS in determining and validating AAV contents: 10:00-11:30 Tips for best practice when using HPLC: 12:30-13:10The future of HPLC: 13:10-14:20Latest advances in AAV development: 14:20-15:50Targeting AAVs: 15:50-17:20Reproducibility issues in AAV development: 17:20-19:35Outro: 19:35-21:10